Bucci T, Romiti G, Shantsila A, Teo W, Park H, Shimizu W
J Am Heart Assoc. 2024; 13(7):e032785.
PMID: 38533983
PMC: 11179754.
DOI: 10.1161/JAHA.123.032785.
Verma M, Sangeeta K, Verma B, Dubey D, Mondal M, Mazumder M
Public Health Pract (Oxf). 2024; 7:100481.
PMID: 38419738
PMC: 10901132.
DOI: 10.1016/j.puhip.2024.100481.
Huang K, Zheng Z, Li W, Niu H, Lei J, Dong F
Lancet Reg Health West Pac. 2024; 42:100937.
PMID: 38357399
PMC: 10865049.
DOI: 10.1016/j.lanwpc.2023.100937.
Yang Z, Kwok M, Schooling C
BMJ Open. 2022; 12(3):e050080.
PMID: 35321891
PMC: 8943480.
DOI: 10.1136/bmjopen-2021-050080.
Xu J, Li L, Ren J, Zhong X, Xie C, Zheng A
Front Cell Dev Biol. 2022; 9:792027.
PMID: 35198563
PMC: 8859106.
DOI: 10.3389/fcell.2021.792027.
Development and validation of a prediction index for recent mortality in advanced COPD patients.
Tsai S, Shih C, Kuo C, Liao X, Lin P, Chen C
NPJ Prim Care Respir Med. 2022; 32(1):2.
PMID: 35027570
PMC: 8758667.
DOI: 10.1038/s41533-021-00263-7.
Trend of Mortality and Years of Life Lost Due to Chronic Obstructive Pulmonary Disease in China and Its Provinces, 2005-2020.
Liu W, Wang W, Liu J, Liu Y, Meng S, Wang F
Int J Chron Obstruct Pulmon Dis. 2021; 16:2973-2981.
PMID: 34744434
PMC: 8565891.
DOI: 10.2147/COPD.S330792.
Chronic respiratory disease mortality and its associated factors in selected Asian countries: evidence from panel error correction model.
Baptista E, Dey S, Pal S
BMC Public Health. 2021; 21(1):53.
PMID: 33407306
PMC: 7788752.
DOI: 10.1186/s12889-020-10042-7.
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.
Halpin D, Criner G, Dransfield M, Han M, Hartley B, Harvey C
Pulm Ther. 2020; 7(1):101-118.
PMID: 33201438
PMC: 8137798.
DOI: 10.1007/s41030-020-00136-3.
Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study.
Chen R, Gao Y, Wang H, Shang H, Xuan J
Int J Chron Obstruct Pulmon Dis. 2020; 15:963-971.
PMID: 32440108
PMC: 7210029.
DOI: 10.2147/COPD.S234349.
Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study.
Zhong N, Zheng J, Lee S, Lipson D, Du X, Wu S
Int J Chron Obstruct Pulmon Dis. 2020; 15:809-819.
PMID: 32368027
PMC: 7173840.
DOI: 10.2147/COPD.S215011.
"High-Risk" Clinical and Inflammatory Clusters in COPD of Chinese Descent.
Tiew P, Ko F, Narayana J, Poh M, Xu H, Neo H
Chest. 2020; 158(1):145-156.
PMID: 32092320
PMC: 7339237.
DOI: 10.1016/j.chest.2020.01.043.
Air Pollution in a Nationally Representative Sample: Findings from the National Adult Tobacco Survey of Lao PDR.
Hurd-Kundeti G, Petersen A, Somsamouth K, Singh P
Int J Environ Res Public Health. 2019; 16(18).
PMID: 31546881
PMC: 6765985.
DOI: 10.3390/ijerph16183500.
Comparison of clinical baseline characteristics between Asian and Western COPD patients in a prospective, international, multicenter study.
Kim K, Miravitlles M, Sliwinski P, Costello R, Carter V, Tan J
Int J Chron Obstruct Pulmon Dis. 2019; 14:1595-1601.
PMID: 31440042
PMC: 6664421.
DOI: 10.2147/COPD.S208245.
Validation of the GOLD 2017 and new 16 subgroups (1A-4D) classifications in predicting exacerbation and mortality in COPD patients.
Han M, Hsiue T, Tsai S, Huang T, Liao X, Chen C
Int J Chron Obstruct Pulmon Dis. 2018; 13:3425-3433.
PMID: 30425472
PMC: 6203118.
DOI: 10.2147/COPD.S179048.
A comparison of spatial heterogeneity with local cluster detection methods for chronic respiratory diseases in Thailand.
Laohasiriwong W, Puttanapong N, Luenam A
F1000Res. 2018; 6:1819.
PMID: 29657710
PMC: 5874503.
DOI: 10.12688/f1000research.12128.2.
Study Design of VESUTO: Efficacy of Tiotropium/Olodaterol on Lung Hyperinflation, Exercise Capacity, and Physical Activity in Japanese Patients with Chronic Obstructive Pulmonary Disease.
Ichinose M, Minakata Y, Motegi T, Ueki J, Seki T, Anzai T
Adv Ther. 2017; 34(7):1622-1635.
PMID: 28537001
PMC: 5504218.
DOI: 10.1007/s12325-017-0554-3.
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha J, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C
Int J Chron Obstruct Pulmon Dis. 2017; 12:339-349.
PMID: 28176893
PMC: 5261570.
DOI: 10.2147/COPD.S125058.
Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities.
Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B
Int J Chron Obstruct Pulmon Dis. 2016; 11:2625-2632.
PMID: 27799761
PMC: 5079691.
DOI: 10.2147/COPD.S118523.
Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
Li Q, Wang Y, Liu L, Ma P, Ding L
Eur J Drug Metab Pharmacokinet. 2016; 42(3):371-381.
PMID: 27306372
DOI: 10.1007/s13318-016-0343-4.